The present invention describes new derivatives of S-allyicysteine with antioxidant and antiaging activity. Said derivatives can be used alone or in a combined formulation with other compounds with known activity.
C07C 323/59 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
C07C 69/76 - Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a six-membered aromatic ring
C07C 69/003 - Esters of saturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
C07C 67/03 - Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
35 - Advertising and business services
Goods & Services
COSMETICS Business management services relating to franchising in the fields of pharmaceutical preparations and homeopathic pharmaceuticals made from plant oils and herbal extracts which can be used for powdered nutritional supplement drink mix, food supplements, hygiene, cosmetics, sanitizers and antibiotics; import and export agencies in the fields of pharmaceutical preparations and homeopathic pharmaceuticals made from plant oils and herbal extracts which can be used for powdered nutritional supplement drink mix, food supplements, hygiene, cosmetics, sanitizers and antibiotics
36 - Financial, insurance and real estate services
Goods & Services
[ Business management services relating to franchising in the fields of pharmaceutical preparations and homeopathic pharmaceuticals made from plant oils and herbal extracts which can be used for powdered nutritional supplement drink mix, food supplements, hygiene, cosmetics, sanitizers and antibiotics; import and export agencies in the fields of pharmaceutical preparations and homeopathic pharmaceuticals made from plant oils and herbal extracts which can be used for powdered nutritional supplement drink mix, food supplements, hygiene, cosmetics, sanitizers and antibiotics ] Private equity fund investment services; venture capital fund management; Financial services, namely, investment management, investment consultation and investment of funds for others, including private and public equity and debt investment services; Financial services, namely, investment fund transfer and transaction services
7.
PHARMACEUTICAL COMPOSITION COMPRISING DESLORATADINE AND PREDNISOLONE AND USE THEREOF
The present invention relates to a liquid pharmaceutical composition for oral administration and to the use thereof, said composition being characterized by comprising: (i) a therapeutically effective quantity of desloratadine or a pharmaceutically acceptable salt thereof; (ii) a therapeutically effective quantity of prednisolone or a pharmaceutically acceptable salt thereof; (iii) a selection of pharmaceutically acceptable excipients wherein the flavouring excipient used is free of vanillin and derivatives thereof, and wherein the pH of said composition is maintained at a value of between 6.0 and 7.5. In the preferred embodiment, the composition of the invention is an antihistamine composition for oral administration, in the form of sugar-free syrups, for paediatric use.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4465 - Non-condensed piperidines, e.g. piperocaine only substituted in position 4
The present invention is designed to provide a solid pharmaceutical composition comprising: (a) an antibacterially effective amount of an antibiotic of the quinolone family, preferentially moxifloxacin or a pharmaceutically acceptable salt thereof; and (b) a vehicle or excipients that are pharmacologically acceptable and compatible with the active ingredient, said excipient being lactose-free. The invention also includes a method for producing a solid pharmaceutical composition comprising, as active principle, an antibiotic of the quinolone family, said method comprising the steps of (a) in a granulator, mixing and homogenizing the active principle and the dry excipients, i.e. either at least one diluent or at least one disintegrant; (b) dissolving the at least one binder in an organic solvent selected from the group comprising isopropyl alcohol, acetone, ethanol, dichloromethane or mixtures thereof; (c) granulating the dry mixture from step (a) with the solution of step (b); (d) at a suitable temperature, grading and drying the granulate from step (c); (e) grading the dry granulate; and (f) mixing and homogenizing the granulate from step (e) with an additional amount of disintegrant in order to produce the composition of the invention.
PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-α MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES
Universidade Estadual Paulista Julio de Mesquita Filho - UNESP (Brazil)
Inventor
Santos, Jean Leandro Dos Santos
Vizioli, Ednir De Oliveira
Chin, Chung Man
Menegon, Renato Farina
Blau, Lorena
Abstract
The present invention relates to phthalimide derivatives of non-steroidal anti-inflammatory compounds and/or TNF-α modulators, to a method for producing these derivatives, to pharmaceutical compositions containing these derivatives, and to uses thereof, including the use for the treatment of inflammatory diseases, in particular those associated with chronic inflammatory conditions, such as rheumatoid arthritis, and inflammatory intestinal diseases (such as Crohn's disease), and to the use of these compositions as antipyretics, analgesics and platelet aggregation inhibitors.
C07D 209/48 - Iso-indolesHydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atomEsters thereof
C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
C07C 229/40 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
C07C 57/40 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic containing condensed ring systems
C07C 65/34 - Compounds having carboxyl groups bound to carbon atoms of six-membered aromatic rings and containing any of the groups OH, O-metal, —CHO, keto, ether, groups, groups, or groups containing keto groups polycyclic
C07C 209/28 - Preparation of compounds containing amino groups bound to a carbon skeleton by reductive alkylation of ammonia, amines or compounds having groups reducible to amino groups, with carbonyl compounds by reduction with other reducing agents
C07C 245/08 - Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/655 - Azo (—N=N—), diazo (=N2), azoxy (N—O—N or N(=O)—N), azido (—N3) or diazoamino (—N=N—N) compounds
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention relates to a composition and pharmaceutical formulation comprising a mixture of an effective amount of powders or granulates of a compound derived from leucine and at least one pharmaceutically acceptable excipient used as the carrier. In particular, the main feature of the formulation and composition that form the subject matter of the present invention is that they are devoid of stabilisers and can be included in any conventional pharmaceutical formulation for oral administration.
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
UNIVERSIDADE ESTADUAL PAULISTA JULIO DE, MESQUITA FILHO - UNESP (Brazil)
Inventor
Vizioli , Ednir De Oliveira
Chin, Chung Man
Menegon, Renato Farina
Blau, Lorena
Santos, Jean Leandro Dos
Longo, Maria Do Carmo
Abstract
The present invention relates to compounds derived from taurine with non-steroidal anti inflammatory activity. In a first embodiment, the present invention relates to compounds derived from taurine, in which taurine is bound directly by means of an amide bond or through an spacing group, to a compound selected from the group of non-steroidal anti inflammatory compounds, cited as derived from taurine presenting the Formula (I): in which R means the component with non-steroidal anti inflammatory activity. In a second embodiment, the invention provides a process for obtaining the compounds of Formula (I) by reaction of taurine with a compound belonging to the group of non-steroidal anti inflammatory (NSAIs), in order to obtain a compound derived from taurine by direct bond or through a spacing group of the taurine to the NSAI. The invention also relates to the pharmaceutical compositions comprising at least one compound derived from taurine presenting non-steroidal anti inflammatory activity.
C07C 309/14 - Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
A delivery system for water-insoluble pharmaceutical active ingredients is provided. The delivery system includes water-insoluble pharmaceutical active ingredient(s), organic solvent(s) and amphiphilic co-sol vent(s), and a mixture of hydrophilic and hydrophobic none ionic surfactants. Upon dilution in an aqueous medium, this formulation forms spontaneously dispersion of non-ionic surfactant nanoparticles.
